+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Wockhardt Ltd (WOCKPHARMA) - Financial and Strategic SWOT Analysis Review

Wockhardt Ltd (WOCKPHARMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Wockhardt Ltd (Wockhardt) is a pharmaceutical company that manufactures and markets vaccines, active pharmaceutical ingredients, formulations and biosimilars. Its product portfolio caters to various therapeutic areas including orthopedics, dental care, dermatology, rheumatology, gynecology, pediatrics, cardiology, pain management, nephrology, neurology and diabetes. The company also concentrates its research in new chemical entities (NCE), generics, abbreviated new drug applications (ANDAs), biosimilars, novel drug delivery systems (NDDS). It operates in India, the US, the UK and the emerging markets. Wockhardt is headquartered in Mumbai, Maharashtra, India.

Wockhardt Ltd Key Recent Developments

Nov 14,2023: Wockhardt Reports an Excellent Quarter Q2 Revenue Jumps by 11%
Aug 14,2023: Wockhardt’s Q1 FY24 3 Fold Growth in EBITDA Over Q1 FY23
Aug 14,2023: Wockhardt : Financial Results
Jul 18,2023: Wockhardt : Appointment of Ms. Amelia Fernandes as Additional (Independent) Director of the Company

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Wockhardt Ltd - Key Facts
  • Wockhardt Ltd - Key Employees
  • Wockhardt Ltd - Key Employee Biographies
  • Wockhardt Ltd - Major Products and Services
  • Wockhardt Ltd - History
  • Wockhardt Ltd - Company Statement
  • Wockhardt Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Wockhardt Ltd - Business Description
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: India
  • Performance
  • Geographical Segment: Rest of World
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Wockhardt Ltd - Corporate Strategy
  • Wockhardt Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Wockhardt Ltd - Strengths
  • Wockhardt Ltd - Weaknesses
  • Wockhardt Ltd - Opportunities
  • Wockhardt Ltd - Threats
  • Wockhardt Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Wockhardt Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Nov 14, 2023: Wockhardt Reports an Excellent Quarter Q2 Revenue Jumps by 11%
  • Aug 14, 2023: Wockhardt’s Q1 FY24 3 Fold Growth in EBITDA Over Q1 FY23
  • Aug 14, 2023: Wockhardt : Financial Results
  • Jul 18, 2023: Wockhardt : Appointment of Ms. Amelia Fernandes as Additional (Independent) Director of the Company
  • May 26, 2023: Wockhardt’s Q4 FY23 3 Fold Jump in EBITDA over Q4 FY22
  • Feb 13, 2023: Wockhardt’s Q3 FY23 EBITDA Growth 37% Over Q2 FY23
  • Nov 04, 2022: Wockhardt’s Q2 FY23 Topline growth 14% and EBITDA growth 369% over previous quarter
  • Aug 20, 2022: Wockhardt : Re-structuring of US business
  • Aug 12, 2022: Wockhardt’s Q1 FY23 EBITDA at Rs.(16 cr) EBITDA before R&D at Rs.20 cr
  • May 30, 2022: Wockhardt’s FY22 Revenue grew by 17% over FY21. Long Term Debt reduced by Rs 450 Cr. Successful Rights Issue of Rs.748 Cr.
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact Us
  • Disclaimer
List of Tables
  • Wockhardt Ltd, Key Facts
  • Wockhardt Ltd, Key Employees
  • Wockhardt Ltd, Key Employee Biographies
  • Wockhardt Ltd, Major Products and Services
  • Wockhardt Ltd, History
  • Wockhardt Ltd, Other Locations
  • Wockhardt Ltd, Subsidiaries
  • Wockhardt Ltd, Key Competitors
  • Wockhardt Ltd, Ratios based on current share price
  • Wockhardt Ltd, Annual Ratios
  • Wockhardt Ltd, Annual Ratios (Cont...1)
  • Wockhardt Ltd, Annual Ratios (Cont...2)
  • Wockhardt Ltd, Interim Ratios
  • Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Wockhardt Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Wockhardt Ltd, Performance Chart (2019 - 2023)
  • Wockhardt Ltd, Ratio Charts
  • Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Dr. Reddy's Laboratories Ltd
  • Sun Pharmaceutical Industries Ltd
  • Sandoz Inc
  • Alcon Inc
  • Cipla Ltd
  • ANI Pharmaceuticals Inc